Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility

Pembrolizumab was safely administered, without identifiable irAEs, and a robust clinical response in a patient with dMMR EC, where the clinical benefit of immunotherapy has been well established. Historically, patients with MG have been excluded from enrollment and treatment on clinical trials. Real world, pragmatic, clinical data may help inform expanded utilization beyond trial eligibility criteria.